A study of AB-423 in the treatment of Hepatitis B
Phase of Trial: Phase I
Latest Information Update: 03 Aug 2017
At a glance
- Drugs AB 423 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- 03 Aug 2017 According to an Arbutus Biopharma Corporation media release, top-line results from this trial are expected in the fourth quarter of 2017.
- 31 Mar 2017 Status changed from planning to recruiting, as reported in an Arbutus Biopharma media release.
- 21 Mar 2017 Aaccording to an Arbutus Biopharma media release, this study will initiate in 1Q 2017.